Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Syst Biol ; 8: 590, 2012 Jun 26.
Article in English | MEDLINE | ID: mdl-22735336

ABSTRACT

Seven-transmembrane receptors (7TMRs) are involved in nearly all aspects of chemical communications and represent major drug targets. 7TMRs transmit their signals not only via heterotrimeric G proteins but also through ß-arrestins, whose recruitment to the activated receptor is regulated by G protein-coupled receptor kinases (GRKs). In this paper, we combined experimental approaches with computational modeling to decipher the molecular mechanisms as well as the hidden dynamics governing extracellular signal-regulated kinase (ERK) activation by the angiotensin II type 1A receptor (AT(1A)R) in human embryonic kidney (HEK)293 cells. We built an abstracted ordinary differential equations (ODE)-based model that captured the available knowledge and experimental data. We inferred the unknown parameters by simultaneously fitting experimental data generated in both control and perturbed conditions. We demonstrate that, in addition to its well-established function in the desensitization of G-protein activation, GRK2 exerts a strong negative effect on ß-arrestin-dependent signaling through its competition with GRK5 and 6 for receptor phosphorylation. Importantly, we experimentally confirmed the validity of this novel GRK2-dependent mechanism in both primary vascular smooth muscle cells naturally expressing the AT(1A)R, and HEK293 cells expressing other 7TMRs.


Subject(s)
Arrestins/metabolism , G-Protein-Coupled Receptor Kinase 2/metabolism , G-Protein-Coupled Receptor Kinases/metabolism , GTP-Binding Proteins/metabolism , Models, Biological , Signal Transduction , Cell Line , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/metabolism , G-Protein-Coupled Receptor Kinase 3/metabolism , G-Protein-Coupled Receptor Kinase 5/metabolism , Humans , Kidney/cytology , Kidney/embryology , Kidney/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Receptor, Angiotensin, Type 1/metabolism , beta-Arrestins
2.
Endocrinology ; 151(6): 2788-99, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20332198

ABSTRACT

The injection of equine chorionic gonadotropin (eCG) in dairy goats induces the production of anti-eCG antibodies (Abs) in some females. We have previously shown that Abs negatively modulate the LH and FSH-like bioactivities of eCG, in most cases, compromising fertility in treated females. Surprisingly, we found out that some anti-eCG Abs improved fertility and prolificity of the treated females, in vivo. These Abs, when complexed with eCG, enhanced LH and FSH ability to induce steroidogenesis on specific target cells, in vitro. In the present study, we analyzed the impact of three eCG/anti-eCG Ab-enhancing complexes on two transduction mechanisms triggered by the FSH receptor: guanine nucleotide-binding protein alphaS-subunit/cAMP/protein kinase A (PKA) and beta-arrestin-dependent pathways, respectively. In all cases, significant enhancing effects were observed on ERK phosphorylation compared with eCG alone. However, cAMP production and PKA activation induced by eCG could be differently modulated by Abs. By using a pharmacological inhibitor of PKA and small interfering RNA-mediated knock-down of endogenous beta-arrestin 1 and 2, we demonstrated that signaling bias was induced and was clearly dependent on the complexed Ab. Together, our data show that eCG/anti-eCG Ab-enhancing complexes can differentially modulate cAMP/PKA and beta-arrestin pathways as a function of the complexed Ab. We hypothesize that enhancing Abs may change the eCG conformation, the immune complex acquiring new "biased" pharmacological properties ultimately leading to the physiological effects observed in vivo. The modulation of ligand pharmacological properties by Abs opens promising research avenues towards the optimization of glycoprotein hormone biological activities and, more generally, the development of new therapeutics.


Subject(s)
Antibodies/immunology , Antigen-Antibody Complex/pharmacology , Chorionic Gonadotropin/immunology , Follicle Stimulating Hormone/metabolism , Gonadotropins, Equine/immunology , Signal Transduction/drug effects , Antigen-Antibody Complex/immunology , Arrestins/metabolism , Cell Line , Cyclic AMP/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Fluorescence Resonance Energy Transfer , Humans , Isoquinolines/pharmacology , Kinetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation/drug effects , RNA, Small Interfering , Sulfonamides/pharmacology , beta-Arrestin 1 , beta-Arrestins
3.
Mol Endocrinol ; 24(3): 561-73, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20107152

ABSTRACT

Deglycosylated FSH is known to trigger poor Galphas coupling while efficiently binding its receptor. In the present study, we tested the possibility that a deglycosylated equine LH (eLHdg) might be able to selectively activate beta-arrestin-dependent signaling. We compared native eLH to an eLH derivative [i.e. truncated eLHbeta (Delta121-149) combined with asparagine56-deglycosylated eLHalpha (eLHdg)] previously reported as an antagonist of cAMP accumulation at the FSH receptor (FSH-R). We confirmed that, when used in conjunction with FSH, eLHdg acted as an antagonist for cAMP accumulation in HEK-293 cells stably expressing the FSH-R. Furthermore, when used alone at concentrations up to 1 nM, eLHdg had no detectable agonistic activity on cAMP accumulation, protein kinase A activity or cAMP-responsive element-dependent transcriptional activity. At higher concentrations, however, a weak agonistic action was observed with eLHdg, whereas eLH led to robust responses whatever the concentration. Both eLH and eLHdg triggered receptor internalization and led to beta-arrestin recruitment. Both eLH and eLHdg triggered ERK and ribosomal protein (rp) S6 phosphorylation at 1 nM. The depletion of endogenous beta-arrestins had only a partial effect on eLH-induced ERK and rpS6 phosphorylation. In contrast, ERK and rpS6 phosphorylation was completely abolished at all time points in beta-arrestin-depleted cells. Together, these results show that eLHdg has the ability to preferentially activate beta-arrestin-dependent signaling at the FSH-R. This finding provides a new conceptual and experimental framework to revisit the physiological meaning of gonadotropin structural heterogeneity. Importantly, it also opens a field of possibilities for the development of selective modulators of gonadotropin receptors.


Subject(s)
Arrestins/metabolism , Luteinizing Hormone/analogs & derivatives , Receptors, FSH/metabolism , Signal Transduction/drug effects , Animals , Blotting, Western , Cattle , Cell Line , Cyclic AMP-Dependent Protein Kinases/metabolism , Enzyme Activation/drug effects , Female , Horses , Humans , Immunoprecipitation , Luteinizing Hormone/chemistry , Luteinizing Hormone/metabolism , Luteinizing Hormone/pharmacology , Mice , Phosphorylation/drug effects , Protein Binding , Protein Transport/drug effects , RNA, Small Interfering , Receptors, FSH/agonists , Receptors, FSH/antagonists & inhibitors , Ribosomal Protein S6/metabolism , Swine , beta-Arrestins
4.
J Endocrinol ; 190(2): 341-50, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16899567

ABSTRACT

FSH-receptor (FSH-R) signaling is regulated by agonist-induced desensitization and internalization. It has been shown, in a variety of overexpression systems, that G protein-coupled receptor kinases (GRKs) phosphorylate the activated FSH-R, promote beta-arrestin recruitment and ultimately lead to internalization. The accuracy of this mechanism has not yet been demonstrated in cells expressing these different molecules at physiological levels. Using sucrose gradient fractionation, we show that FSH induces the recruitment of the endogenous GRK 2 and beta-arrestin 1/2 from the cytoplasm to the plasma membrane of rat primary Sertoli cells. As assessed by ligand binding, the FSH-R was found expressed in the fractions where GRK 2 and beta-arrestins were recruited upon FSH treatment. In addition, the endogenous beta-arrestin 1 was found dephosphorylated in an agonist-dependent manner. Finally, a significant FSH-binding activity was co-immunoprecipitated with the endogenous beta-arrestins from agonist-stimulated but not from untreated Sertoli cell extracts. This FSH-R interaction with beta-arrestins was sustained for up to 30 min. In conclusion, our data strongly suggest that the GRK/beta-arrestin machinery plays a physiologically relevant role in the regulation of the FSH signaling.


Subject(s)
Arrestins/metabolism , Receptors, FSH/metabolism , Receptors, G-Protein-Coupled/metabolism , Sertoli Cells/metabolism , Signal Transduction/physiology , Animals , Cells, Cultured , Follicle Stimulating Hormone/pharmacology , Immunoblotting/methods , Immunoenzyme Techniques , Immunoprecipitation , Male , Phosphorylation , Protease Inhibitors/pharmacology , Protein Binding , Rats , Rats, Wistar , Sertoli Cells/drug effects , Signal Transduction/drug effects , Stimulation, Chemical , beta-Arrestin 1 , beta-Arrestins
5.
Mol Endocrinol ; 20(11): 3014-26, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16887887

ABSTRACT

Classically, the FSH receptor (FSH-R) mediates its effects through coupling to guanine nucleotide-binding protein alpha S subunit (Galpha(s)) and activation of the cAMP/protein kinase A (PKA) signaling pathway. beta-Arrestins are rapidly recruited to the FSH-activated receptor and play key roles in its desensitization and internalization. Here, we show that the FSH-R expressed in HEK 293 cells activated ERK by two temporally distinct pathways dependent, respectively, on Galpha(s)/PKA and beta-arrestins. Galpha(s)/PKA-dependent ERK activation was rapid, transient, and blocked by H89 (a PKA inhibitor), but it was insensitive to small interfering RNA-mediated depletion of beta-arrestins. beta-Arrestin-dependent ERK activation was slower but more sustained and was insensitive to H89. We identified five Ser/Thr residues in the C terminus of the receptor (638-644) as a major phosphorylation site. Mutation of these residues into Ala (5A FSH-R) significantly reduced the stability of FSH-induced beta-arrestin 1 and 2 interaction when compared with the wild-type receptor. As expected, the 5A FSH-R-mediated cAMP accumulation was enhanced, and its internalization was reduced. In striking contrast, the ability of the 5A FSH-R to activate ERK via the beta-arrestin-dependent pathway was increased. G protein-coupled receptor kinase 5 (GRK5) and GRK6 were required for beta-arrestin-dependent ERK activation by both the wild-type and 5A FSH-R. By contrast, GRK2 depletion enhanced ERK activation by the wild-type FSH-R but not by the 5A FSH-R. In conclusion, we demonstrate the existence of a beta-arrestin-dependent, GRK-regulated mechanism for ERK activation by the FSH-R. A phosphorylation cluster in the C terminus of the FSH-R, identified as a site of beta-arrestin recruitment, positively regulated both desensitization and internalization but negatively regulated beta-arrestin-dependent ERK activation.


Subject(s)
Arrestins/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Receptors, FSH/metabolism , Amino Acid Motifs , Amino Acid Sequence , Cells, Cultured , Endocytosis , G-Protein-Coupled Receptor Kinase 2 , Humans , Molecular Sequence Data , Mutant Proteins/metabolism , Phosphorylation , Protein Binding , Protein Interaction Mapping , Protein Structure, Tertiary , Protein Transport , Receptors, FSH/chemistry , Sequence Homology, Amino Acid , Serine/metabolism , Signal Transduction , Threonine/metabolism , beta-Adrenergic Receptor Kinases/metabolism , beta-Arrestin 1 , beta-Arrestins
6.
Reprod Biol Endocrinol ; 4: 33, 2006 Jun 20.
Article in English | MEDLINE | ID: mdl-16787538

ABSTRACT

BACKGROUND: The follicle-stimulating hormone receptor (FSH-R) is a seven transmembrane spanning receptor (7TMR) which plays a crucial role in male and female reproduction. Upon FSH stimulation, the FSH-R activates the extracellular signal-regulated kinases (ERK). However, the mechanisms whereby the agonist-stimulated FSH-R activates ERK are poorly understood. In order to activate ERK, some 7 TMRs require beta-arrestin-and dynamin-dependent internalization to occur, whereas some others do not. In the present study, we examined the ability of the FSH-activated FSH-R to induce ERK phosphorylation, in conditions where its beta-arrestin- and dynamin-mediated internalization was impaired. METHODS: Human embryonic kidney (HEK) 293 cells were transiently transfected with the rat FSH-R. Internalization of the FSH-R was manipulated by co-expression of either a beta-arrestin (319-418) dominant negative peptide, either an inactive dynamin K44A mutant or of wild-type beta-arrestin 1 or 2. The outcomes on the FSH-R internalization were assayed by measuring 125I-FSH binding at the cell surface when compared to internalized 125I-FSH binding. The resulting ERK phosphorylation level was visualized by Western blot analysis. RESULTS: In HEK 293 cells, FSH stimulated ERK phosphorylation in a dose-dependent manner. Co-transfection of the beta- arrestin (319-418) construct, or of the dynamin K44A mutant reduced FSH-R internalization in response to FSH, without affecting ERK phosphorylation. Likewise, overexpression of wild-type beta-arrestin 1 or 2 significantly increased the FSH-R internalization level in response to FSH, without altering FSH-induced ERK phosphorylation. CONCLUSION: From these results, we conclude that the FSH-R does not require beta-arrestin- nor dynamin-mediated internalization to initiate ERK phosphorylation in response to FSH.


Subject(s)
Arrestins/physiology , Dynamins/physiology , Endocytosis/physiology , Extracellular Signal-Regulated MAP Kinases/metabolism , Follicle Stimulating Hormone/physiology , Receptors, FSH/metabolism , Animals , Arrestins/genetics , Cell Line , Cell Membrane/metabolism , Dose-Response Relationship, Drug , Dynamins/genetics , Follicle Stimulating Hormone/administration & dosage , Follicle Stimulating Hormone/metabolism , Follicle Stimulating Hormone/pharmacology , Genes, Dominant , Humans , Mutation , Phosphorylation/drug effects , Rats , Receptors, FSH/drug effects , Transfection , beta-Arrestin 1 , beta-Arrestins
7.
Curr Pharm Des ; 10(5): 449-69, 2004.
Article in English | MEDLINE | ID: mdl-14965333

ABSTRACT

The testis is devoted to two important tasks: haploid cell production and sexual steroid synthesis. A number of highly sophisticated and unique strategies operate during spermatogenesis, a process crucial for reproduction, heredity and evolution. It is particularly important to decipher the underlying molecular mechanisms whose function can be perverted in pathological situations, such as infertility and testicular cancers, which represent an increasing biomedical issue today. This review summarises the currently available data concerning some key molecular components that are altered or potentially involved in male infertility and testicular tumors, with the aim of defining some common "hot spots". We particularly focused on genetically engineered in vivo models in which testicular functions are altered and we pinpointed to the potential involvement of the targeted genes in testicular pathologies. Those molecular mechanisms peculiar to the male gonad can be envisioned as a basis for the design of novel drugs potentially dedicated to testicular dysfunction.


Subject(s)
Infertility, Male/metabolism , Neoplasms, Germ Cell and Embryonal/metabolism , Testicular Neoplasms/metabolism , Animals , Germ Cells/cytology , Germ Cells/growth & development , Humans , Infertility, Male/pathology , Male , Neoplasms, Germ Cell and Embryonal/pathology , Testicular Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...